Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Laboratorios Farmaceuticos Rovi ( (ES:ROVI) ) has shared an announcement.
ROVI has announced that its EBITDA levels for the 2024 fiscal year are expected to fall short by 10% to 15% compared to market consensus, primarily due to lower activity in its contract manufacturing business during the fourth quarter. The complete fiscal results are set to be published on February 25, 2025, but ROVI has confirmed that its forecasts for 2025 remain unchanged, suggesting a potential shift in operational focus or market strategy to stabilize future performance.
More about Laboratorios Farmaceuticos Rovi
Laboratorios Farmacéuticos ROVI, S.A. operates within the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical products. The company is known for its contract manufacturing business and has a market focus on delivering various pharmaceutical solutions.
YTD Price Performance: 4.61%
Average Trading Volume: 2,286
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €3.32B
See more data about ROVI stock on TipRanks’ Stock Analysis page.
